Effect of Shengmai Capsule on Heart Rate Variability in Patients with Schizophrenia Who Administered with Megadose Amisulpride

OBJECTIVE To explore the effect of Shengmai Capsule(SMC) on heart rate variability in patients with schizophrenia who administered with megadose amisulpride. METHODS 100 patients with schizophrenia were randomly divided into the experimental group (50 cases medicated with amisulpride and SMC) and the control group (50 cases medicated only with amisulpride). Time domain analyses including SDNN, SDANN index, SDNN index, RMSSD and pNN50 were adopted to assess differences in HRV before and after 12 week of treatment between the two groups. The positive and negative symptom scale (PANSS) was used in evaluating the clinical efficacy of different groups. The incidence rate of cardiovascular adverse reactions of two groups after treatment was also calculated. RESULTS The SDNN, SDNN index, RMSSD and pNN50 of control group were higher than experimental group (P<0.05). Patients in control group exhibited an increase at SDNN, SDNN index, RMSSD and pNN50 in comparison with pre-treatment (P<0.05). The total incidence rate of cardiovascular adverse reactions in control group was higher than control group after treatment (P<0.05). The clinical efficacy of both two groups had no statistical significance. CONCLUSION The use of megadose amisulpride can increase patients' HRV and result in dysfunction of the cardiac autonomic nervous system. The plus of SMC would obviously reduce those risks.